



Attorney Docket No. 5698.220-US
Jeppesen et al.
Serial No. 10/076,575 Filed February 8, 2002
Express Mail Label No. EV 409532886 US

Attorney Docket No.: 5698.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: 10/076,575

Group Art Unit: 1624

Filed: February 8, 2002

Examiner: Truong, Tamthom Ngo

Confirmation No.: 2403

For: Substituted Hetero-Polycyclic Compounds as PPAR α and PPAR γ Activators (as amended)

RECEIVED

AMENDMENT/RESPONSE

MAR 05 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

Sir:

This amendment is submitted in response to the first Office Action on the merits mailed November 6, 2003, having a shortened statutory period for reply set to expire February 6, 2004, subject to extensions of time under the provisions of 37 CFR §1.136(a).

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this amendment/response, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk Pharmaceuticals, Inc., for any such required fee.

The Examiner states in the Office Action Summary that claims numbered 1, 2, 7, 17, 45-47, and 53-55 are pending in the application; claims numbered 1, 2, 7, 17, 46, 47, and 53-55 are rejected; and claim number 45 is objected to.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application, with current amendments noted.

Claim number 54 has been amended. Claim number 53 has been cancelled. No new matter has been introduced by this amendment.